The Inflation Reduction Act (IRA): How Will It Impact Drug Development? – Webinar Recording/Transcript
Product Details
Are you concerned about the potential impact of the Inflation Reduction Act (IRA) on your drug development efforts?
As part of the IRA, the government’s moves to negotiate prices for some top-selling Medicare Part D drugs will have long-term consequences across the entire pharma sector. That could lead to a loss of investor confidence, come with costly rebates, and possibly stall your drug development efforts.
In this presentation on the IRA, two expert drug development analysts, Ken Getz and Emily Botto from the Tufts Center for the Study of Drug Development (CSDD), examine the landmark legislation’s primary provisions, quantify the impact, and identify strategies drug sponsors need to consider in adapting to the new environment.
Presentation Takeaways:
- Gain a greater understanding of the “big picture” — examining the IRA in its historical context and what it means for the future of drug innovation.
- Analyze in-depth explanations of the IRA legislation’s key provisions.
- Identify the drug development areas that will be most impacted.
- Revise your strategic plans in the face of the IRA’s mandates.
Prepare your drug development business for the enforcement of the Inflation Reduction Act.
Meet Your Presenters
Kenneth Getz is executive director of the Tufts Center for the Study of Drug Development (CSDD) and a research professor in the Tufts University School of Medicine. An internationally recognized expert in R&D and clinical trial management, his more than two decades of original research benchmarking R&D management practices have contributed to improvements in management strategy and execution. Getz is a board member of WCG Clinical, the parent company of FDAnews.
Emily Botto is a senior research analyst at Tufts CSDD. She works on a variety of studies focusing on clinical research execution strategies and practices as well as clinical trial diversity and inclusion.
Who Will Benefit
- Senior level pharma and biotech executives
- Regulatory affairs staff
- Medical affairs staff
- R&D Heads
- Portfolio strategy management staff